Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
12,021 GBX | -0.54% |
|
-4.27% | +13.40% |
03:04pm | ASTRAZENECA : Buy rating from Berenberg | ZD |
10:58am | Aptamer shares jump as inks agreement with AstraZeneca | AN |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+13.40% | 24TCr | |
+55.78% | 82TCr | |
+39.71% | 63TCr | |
-7.39% | 35TCr | |
+15.80% | 32TCr | |
+6.91% | 29TCr | |
+0.78% | 22TCr | |
+13.31% | 22TCr | |
+7.95% | 17TCr | |
-2.87% | 16TCr |
- Stock Market
- Equities
- AZN Stock
- News AstraZeneca PLC
- AstraZeneca's Imfinzi, Lynparza Combination Recommended for Approval in Europe as Endometrial Cancer Treatment